Targets › MICU1
1 program from 1 company in 4 trials: 2 Phase 2, 2 Phase 1; Hematology, Oncology; next expected readout Dec 2026.
Calcium sensor of the mitochondrial calcium uniporter (MCU) channel, which senses calcium level via its EF-hand domains. MICU1 and MICU2 (or MICU3) form a disulfide-linked heterodimer that stimulates and inhibits MCU activity, depending on the concentration of calcium. (UniProt, Q9BPX6)
Open in Phaseline: the race on MICU1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| St. Jude Children's Research Hospital | [13N]NH3 MICU1 inhibitor; mitochondrial calcium uniporter inhibitor | MICU1 | Phase 2 | Frailty; Sickle Cell Disease; Acute Pancreatitis; Acute Lymphoblastic Leukemia, in Relapse | Dec 2026 |
Frailty (1) Sickle Cell Disease (1) Acute Pancreatitis (1) Acute Lymphoblastic Leukemia, in Relapse (1)
small molecule (1)
St. Jude Children's Research Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.